Maximal testosterone suppression in prostate cancer--free vs total testosterone.
Testosterone remains a key target in the treatment of advanced prostate cancer. The relationship of free testosterone to prostate cancer treatment and outcomes remains largely unexplored. A consensus of prostate cancer experts was convened in 2013 to review current knowledge surrounding relationship of total and free testosterone to prostate cancer, discuss the free hormone hypothesis, and highlight future avenues for therapeutics. Free testosterone may better reflect prostate cancer tissue androgen levels than serum total testosterone concentration. Free testosterone deserves more research regarding its relation to clinical outcomes.
Division of Urology, University of Colorado, Anschutz Medical Campus, Aurora, CO. Electronic address: kyle.rove@ucdenver.edu.
Kyle O
KO
Rove
Division of Urology, University of Colorado, Anschutz Medical Campus, Aurora, CO.
E David
ED
Crawford
Ospedale Santo Spirito, Alessandria, Italy.
Massimo
M
Perachino
Autónoma University of Barcelona, Barcelona, Spain.
Juan
J
Morote
Sunnybrook Health Sciences Centre, Toronto, Canada.
Laurence
L
Klotz
University of Washington, Seattle, WA.
Paul H
PH
Lange
Washington University School of Medicine, St. Louis, MO.
Gerald L
GL
Andriole
University of Washington/Veterans Affairs Puget Sound Health Care System, Seattle, WA.
Alvin M
AM
Matsumoto
New York University School of Medicine, New York, NY.
Samir S
SS
Taneja
Johns Hopkins University School of Medicine, Baltimore, MD.
Mario A
MA
Eisenberger
University of Campinas, School of Medical Sciences, UNICAMP, Brazil.
Leonardo O
LO
Reis
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018570:Risk Assessment; D016019:Survival Analysis; D013739:Testosterone / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D016896:Treatment Outcome
D000726:Androgen Antagonists; D014408:Biomarkers, Tumor; D013739:Testosterone; D017430:Prostate-Specific Antigen